Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Ascites 1

Interventions

Oxaliplatin 3Irinotecan 3Surveys and Questionnaires 2Specimen Handling 2Radiosurgery 2Leucovorin 2Ketamine 2Hydroxychloroquine 2Fluorouracil 2Capecitabine 2ulixertinib 1tegafur-gimeracil-oteracil 1regorafenib 1pazopanib 1lanreotide 1fludarabine phosphate 1fludarabine 1dostarlimab 1dolasetron 1dexamethasone acetate 1dexamethasone 21-phosphate 1danvatirsen 1cobimetinib 1brivanib 1auricularum 1atezolizumab 1alectinib 1aldesleukin 1abelacimab 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrointestinal Neoplasms × danvatirsen × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡